The purchase price, which is confidential & was negotiated for a maximum of 300 huge number of doses, is a little less than the $19.50 per photo the United States agreed to buy a first shipment of 100 million doses of the same vaccine, in series with what Reuters claimed in November.
The EU document dated Nov. 18 was circulated internally right after the EU announced its supply package with Pfizer and the German partner BioNTech of its on Nov. 11.
The EU drug regulator is expected to determine on Monday on acceptance for the Pfizer vaccine after the shot was authorised in a few countries, including Britain as well as the United States.
On Thursday Belgian state secretary on your budget Eva De Bleeker released on Twitter a table with prices Belgium would pay pharmaceutical companies for the COVID-19 vaccines of theirs. She retracted the piece of writing shortly after posting.
In this table the Pfizer vaccine was suggested as costing Belgium 12 euros ($14.6) per dose, leading many to think that was the full fee agreed by way of the EU.
Other vaccines in the table were also shown with rates lower compared to rates disclosed by EU sources.
“There is always a total cost and a cost upon delivery,” an EU official involved in talks with vaccine creators told Reuters when made to clarify the big difference between the EU and Belgian rates.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality needs, but pointed to what De Bleeker told the Belgian parliament last week. In that public hearing, De Beeker said Belgium’s budgeted prices were still partial.
Under EU advanced purchase deals for COVID-19 vaccines, the bloc agrees initial payments with companies to secure doses before they’re approved. Following approvals, EU governments are able to pay the remainder to get reserved doses.
The EU has not revealed the initial payment agreed with Pfizer.
Nonetheless, it said in October that it paid about 1 billion euros in downpayments to AstraZeneca, Sanofi and Johnson & Johnson for their shots, with an additional 1.45 billion euros budgeted for upfront payments to Pfizer-BioNTech, Moderna and Curevac.
It’s since agreed source deals with all six organizations and it is negotiating a seventh agreement with Novavax.